SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programme Vrije Universiteit Brussel
Pandemic preparedness against protozoan parasites through the establishment of a hybrid camelid single-domain antibody platform. University of Antwerp
Financing IOF-program: Camelidae-derived single-domain antibody fragments for theranosis of cancer Vrije Universiteit Brussel
Single domain antibodies that neutralize SARS-CoV-2 Ghent University
The aim of this project is to isolate single domain antibodies that are directed against the receptor-binding domain that is part of the spike protein of SARS-CoV-2. Those single-domain antibodies, separately and combined, will be evaluated for their capacity to neutralize SARS-CoV-2.
Evaluation of an in vivo pre-targeting approach for targeted radionuclide therapy of cancer using clickable anti-B7-H3 single domain antibodies. Vrije Universiteit Brussel
approach as it can specifically deliver lethal radiation doses both to
the primary tumour site as well as disseminated disease, while
sparing non-target organs. TRNT using full-sized antibodies as
vectors remains challenging in solid tumours due to their long
circulation time. Single-domain antibody fragments (sdAbs) are
vectors with ...
Influenza B viruses (IBVs) cause a quarter of all human influenza cases and in some seasons even dominate influenza A. In the past 3 decades, the world has witnessed a worrying antigenic diversification of IBVs, first with the emergence in the 1980s of the steadily separating Victoria and Yamagata antigenic lineages. More recently, the Yamagata lineage in its turn has started to bifurcate antigenically. In general, currently licensed ...
Perturbation of apolipoprotein E4 (apoE4) activity in AD pathology using single domain antibodies and targeting them to the brain Ghent University
The APOE-ε4 allele is the most prominent genetic risk factor for late onset AD. We will use ApoE4 nanobodies to stabilize the non-pathological conformation of ApoE4, and use photoporation as a means of introducing nanobodies in mammalian cells. In addition, we plan to target nanobodies to the brain in collaboration with prof. Breakefield (Dept. Neurology, Harvard Medical School, Boston).